Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO EQUITY RATIO
N/A
Conexeu Sciences Inc.
Market Cap
$83.49M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.96M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$84.70M
Debt to Equity Ratio
N/A
TTM Avg
0.33
3Y Avg
0.19
5Y Avg
0.13
Market Cap
$84.75M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$81.22M
Debt to Equity Ratio
0.25
TTM Avg
0.08
3Y Avg
0.04
5Y Avg
0.04
Market Cap
$79.46M
Debt to Equity Ratio
1.83
TTM Avg
0.28
3Y Avg
0.24
5Y Avg
0.19
Market Cap
$87.86M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.02
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | $83.49M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | 0.02 | 0.03 | 0.04 | 0.03 |
| Humacyte, Inc. (HUMA)vs › | $84.00M | 2.12 | 20.86 | 8.51 | 5.27 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | N/A | 0.33 | 0.19 | 0.13 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | 0.02 | 0.02 | 0.03 | 0.03 |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | 0.25 | 0.08 | 0.04 | 0.04 |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 3.10 | 0.07 | 0.16 | 0.15 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | 1.83 | 0.28 | 0.24 | 0.19 |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | 0.02 | 0.02 | 0.03 | 0.02 |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 0.40 | 0.52 | 0.53 | 0.47 |
Debt/Equity
N/A
Current Ratio
N/A
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
